Key comments by CEO during Gateway radio interview in UK mid-day...

Key comments by CEO during Gateway radio interview in UK mid-day Wednesday highlighting World Laboratory Day:

• We have a drug that acts as a physical barrier for these patients. It also repairs the skin, makes it smoother and better and assists in repair of DNA that is damaged by the UV.
• The most prominent feature is that we have a unique drug that activates the tanning of patients without actually exposing to the sun.
• Injecting afamelanotide every 2 months patients become visibly bronze as a by-product.  Some patients love it because it gives the appearance of having been in Spain all year round without actually having been exposed to the sun.  The by-product of tanning is that you develop a pigment layer that absorbs the light that is damaging to these patients.
• The treatment is proven revolutionary to these patients.
• Vitiligo – mental health is also a factor.  Losing their identity, their ethnic charactistics.  Scenesse reverses the depigmentation and brings back the pigmentation to how they had been born.  Quite revolutionary and we saw that in PII trials in North America and with the PIII they are so thrilled and content the patients are sharing their pictures.  Psychology in this is huge.
• XP & Stroke – a unique set of decision factors.  A trilogy of decisions to decide whether to allocate the funds to pursue.  Can you obtain marketing approval, what are the chances?  Is there an alternative therapy or are we unique?  Objective is to pursue where there is an unmet need.  Only 4% of potential drugs come to market.  96% fail.  Will insurers pay for the treatment?  This is the trilogy of decisions in deciding where to allocate funds.
• VP – indicated it is worthwhile, insurers will reimburse.

e&oe.  This is as heard from the interview.  It appeared as though the interviewer was provided with the questions.  Thanks to Cobalt from elsewhere for the link.